Table 5.

Randomized trials comparing LMWH with AVK for cancer-related VTE secondary prophylaxis

Clinical trial/year	Study drug	N	Observation period	Recurrent VTE (VKA vs. LMWH)	Major bleeding (VKA vs. LMWH)	Mortality (VKA vs. LMWH)
CLOT 2003	Dalteparin 25 % LMWH dose reduction after 1 month	672	6 months	17 vs. 9 %; p = 0.02	4 vs. 6 %; p = 0.27	41 vs. 39 %; p = 0.53
CANTHANOX 2002	Enoxaparin full dose once daily	146	3 months	21.1 vs. 10.5 %; p = 0.09	16 vs. 7 %; p = 0.09	22.7 vs. 11.3 %; p = 0.07
ONCENOX 2006	Enoxaparin 2 full-dose schemes (twice and once daily)a	122	6 months	10 vs. 6.9 vs. 6.3. %; p = NS	2.9 vs. 6.5 vs. 11.1 %; p = NS	32.4 vs. 22.6 vs. 41.7 %; p = NS
LITE 2006	Tinzaparin full dose	200	3 months	16 vs, 7 %; p = 0.044	7 vs. 7 %; p = NS	19 vs. 20 %; p = NS

^aAVK vs. enoxaparin 1 mg/KG/12 h and AVK vs. enoxaparin 1.5 mg/kg/day